Charles M Farber 1144218215

Dr. Charles M Farber, MD

Claim this profile

Morristown Medical Center

Studies Lung Cancer
Studies Lymphoma
19 reported clinical trials
39 drugs studied

Area of expertise

1Lung Cancer
Charles M Farber, MD has run 5 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Lymphoma
Charles M Farber, MD has run 5 trials for Lymphoma. Some of their research focus areas include:
Stage I
Stage II
Stage III

Affiliated Hospitals

Image of trial facility.
Morristown Medical Center
Image of trial facility.
Overlook Hospital

Clinical Trials Charles M Farber, MD is currently running

Image of trial facility.

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Charles M Farber, MD

Clinical Trial Related13 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Charles M Farber, MD has experience with
  • Pembrolizumab
  • Brentuximab Vedotin
  • Carboplatin
  • Pemetrexed
  • Nivolumab
  • Dacarbazine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Charles M Farber, MD specialize in?
Is Charles M Farber, MD currently recruiting for clinical trials?
Are there any treatments that Charles M Farber, MD has studied deeply?
What is the best way to schedule an appointment with Charles M Farber, MD?
What is the office address of Charles M Farber, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security